# A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies

> **NCT06894693** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Guangdong Ruishun Biotech Co., Ltd** · enrollment: 13 (estimated)

## Conditions studied

- B-cell Non-Hodgkin's Lymphoma
- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** RS001 injection

## Key facts

- **NCT ID:** NCT06894693
- **Lead sponsor:** Guangdong Ruishun Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2026-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2025-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06894693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06894693, "A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06894693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*